180 related articles for article (PubMed ID: 37354155)
1. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy.
Fahmy AS; Rowin EJ; Jaafar N; Chan RH; Rodriguez J; Nakamori S; Ngo LH; Pradella S; Zocchi C; Olivotto I; Manning WJ; Maron M; Nezafat R
JACC Cardiovasc Imaging; 2024 Jan; 17(1):16-27. PubMed ID: 37354155
[TBL] [Abstract][Full Text] [Related]
2. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
[TBL] [Abstract][Full Text] [Related]
3. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.
Wang J; Yang S; Ma X; Zhao K; Yang K; Yu S; Yin G; Dong Z; Song Y; Cui C; Li J; Wang C; Hao J; Lu M; Chen X; Zhao S
Eur Heart J; 2023 Dec; 44(45):4781-4792. PubMed ID: 37795986
[TBL] [Abstract][Full Text] [Related]
4. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
[TBL] [Abstract][Full Text] [Related]
5. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
[TBL] [Abstract][Full Text] [Related]
6. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
7. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
[TBL] [Abstract][Full Text] [Related]
8. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
He D; Ye M; Zhang L; Jiang B
Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
[TBL] [Abstract][Full Text] [Related]
11. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Late Gadolinium Enhancement Cardiac Magnetic Resonance and Sudden Death in Hypertrophic Cardiomyopathy: A Meta-Analysis.
Kiaos A; Daskalopoulos GN; Kamperidis V; Ziakas A; Efthimiadis G; Karamitsos TD
JACC Cardiovasc Imaging; 2024 May; 17(5):489-497. PubMed ID: 37632503
[TBL] [Abstract][Full Text] [Related]
14. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis.
Kamp NJ; Chery G; Kosinski AS; Desai MY; Wazni O; Schmidler GS; Patel M; Lopes RD; Morin DP; Al-Khatib SM
Prog Cardiovasc Dis; 2021; 66():10-16. PubMed ID: 33171204
[TBL] [Abstract][Full Text] [Related]
16. Radiomics Analysis Derived From LGE-MRI Predict Sudden Cardiac Death in Participants With Hypertrophic Cardiomyopathy.
Wang J; Bravo L; Zhang J; Liu W; Wan K; Sun J; Zhu Y; Han Y; Gkoutos GV; Chen Y
Front Cardiovasc Med; 2021; 8():766287. PubMed ID: 34957254
[No Abstract] [Full Text] [Related]
17. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
Green JJ; Berger JS; Kramer CM; Salerno M
JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
[TBL] [Abstract][Full Text] [Related]
18. Late Gadolinium Enhancement-Dispersion Mapping: A New Magnetic Resonance Imaging Technique to Assess Prognosis in Patients With Hypertrophic Cardiomyopathy and Low-Intermediate 5-Year Risk of Sudden Death.
Aquaro GD; Grigoratos C; Bracco A; Proclemer A; Todiere G; Martini N; Habtemicael YG; Carerj S; Sinagra G; Di Bella G
Circ Cardiovasc Imaging; 2020 Jun; 13(6):e010489. PubMed ID: 32539460
[TBL] [Abstract][Full Text] [Related]
19. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy.
Zegkos T; Tziomalos G; Parcharidou D; Ntelios D; Papanastasiou CA; Karagiannidis E; Gossios T; Rouskas P; Katranas S; Paraskevaidis S; Karvounis H; Efthimiadis G
Hellenic J Cardiol; 2022; 63():15-21. PubMed ID: 34147674
[TBL] [Abstract][Full Text] [Related]
20. High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy.
Gommans DHF; Cramer GE; Bakker J; Dieker HJ; Michels M; Fouraux MA; Marcelis CLM; Verheugt FWA; Timmermans J; Brouwer MA; Kofflard MJM
Int J Cardiovasc Imaging; 2018 Jan; 34(1):113-120. PubMed ID: 29063221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
